We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
- Authors
Lynce, Filipa; Mainor, Candace; Donahue, Renee N.; Geng, Xue; Jones, Greg; Schlam, Ilana; Wang, Hongkun; Toney, Nicole J.; Jochems, Caroline; Schlom, Jeffrey; Zeck, Jay; Gallagher, Christopher; Nanda, Rita; Graham, Deena; Stringer-Reasor, Erica M.; Denduluri, Neelima; Collins, Julie; Chitalia, Ami; Tiwari, Shruti; Nunes, Raquel
- Abstract
This document is a correction notice for an article titled "Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study" published in Nature Communications. The correction addresses inaccuracies in the original version of the article. The corrections include changes to the abstract, results, discussion, and other sections of the article. The revised versions of the article now accurately reflect the findings of the study. The authors of the article are Filipa Lynce, Candace Mainor, Renee N. Donahue, and several others.
- Subjects
TRIPLE-negative breast cancer; NIVOLUMAB
- Publication
Nature Communications, 2024, Vol 15, Issue 1, p1
- ISSN
2041-1723
- Publication type
Correction Notice
- DOI
10.1038/s41467-024-46961-x